MTOR and neoplasm: Although PTEN-loss has not been formally linked to synergistic pharmacologic interactions between MAPK and PI3K/mTOR inhibitors, careful analysis of published evidence suggests that such combination provides more striking tumor control in PTEN-loss, as compared with PTEN-competent, preclinical models.